Clinical Trials Browser

Phase 3 × osimertinib × 30 days × Clear all

NCT04487080 2026-04-22

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04181060 2026-04-21

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT04765059 2026-04-21

COMPEL

Phase 3 Active not recruiting

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

Phase 3 Active not recruiting

Neoplasms

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma